1 an update on ich guideline q8 – pharmaceutical development fda advisory committee for...
Post on 03-Jan-2016
223 Views
Preview:
TRANSCRIPT
1
An Update on ICH Guideline Q8 – Pharmaceutical DevelopmentFDA Advisory Committee for Pharmaceutical
Science: 5 Oct 2006
Dr John C BerridgeSenior Regulatory ConsultantPfizer ISPE Vienna Congress 2006
2
Presentation Outline
Background to Q8 Experience of Q8 to date Implications of Q8 Future strategy for Q8
3
July 2003: An ICH vision
Existing Existing GMPGMP’’ss
Quality by Design(Pharmaceutical
Development)
Quality Risk Management
The Regulatory Quality System
Our vision: The future Pharmaceutical Quality System
Quality Systems
Quality Systems (Q10)
For companies with :1. Good design and
control strategies2. Good Risk
Management strategies3. Good Quality Systems
Quality Risk Management
(Q9)
Quality by Design
(Q8)
Reduced regulatory burden:
• Reduction of submissions on changes/variations
• Inspection of quality systems
4
Q8– an opportunity for change
Empirical
Data Driven
Retrospective
“Test to document quality”
Acceptance criteria based on limited batch data
Variability not understood and avoided
Systematic
Knowledge driven
Prospective
Science and Risk based
Acceptance criteria based on patient needs
Variability explored and understood (Design Space)
Q8
Traditional Future
5
On July 20th 2004 you were told Q8 could deliver:-
Product quality and performance achieved and assured by design of effective and efficient manufacturing processes
Product specifications based on mechanistic understanding of how formulation and process factors impact product performance
An ability to effect Continuous Improvement and Continuous "real time" assurance of quality
6
The EWG has delivered the core guideline
Part 1Core document Baseline expectationsOptional informationRegulatory Flexibility
Q8 is a 2 part guidelineQ8 is a 2 part guideline
Step 4: Nov 2005
RevisionAnnexes relating to specific dosage forms (as Q6a)References to use of risk managementFocus on guiding towards Desired State
Drafting underway
7
Presentation Outline
Background to Q8 Experience of Q8 to date Implications of Q8 Future strategy for Q8
8
We have recognised Q8 encourages a new development paradigm – Quality by Design
Target Product
Profile
Define product intended use & quality targets (wrt efficacy & safety)
Product/ Process DesignSpace
Through hypothesis testing, create scientific understanding of product and process. Identify ’critical to quality attributes’ and establish multi-variate ”Design Space” that assures Quality
Control Strategy
Define control strategy based on Quality Risk Mgmt & Design Space leading to control of quality relevant to safety and efficacy.
Product/ Process
Dev.
Incorporate prior knowledge, Risk Assessment, DoE and PAT to create New Scientific Knowledge,
9
To provide a product that consistently meets their needs….
..we need to manufacture by a process that is well understood,
robust, but adaptable…
… to the variability of input materials-API, Excipients etc
= DESIGN SPACE
Quality by Design starts with the Patient, delivers consistently to the patient, but welcomes variability!
10
Design Space: 3 key concepts
Design Space: the multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality.
Working within the design space is not considered as a change. Movement out of the design space is considered to be a change and would normally initiate a regulatory post approval change process.
Design space is proposed by the applicant and is subject to regulatory assessment and approval.
11
Q8 applies throughout product life-cycle
Product Development
Design quality product & process to consistently deliver intended performance.
Knowledge gained from development studies & manufacturing experience provide scientific understanding to support the establishment of the design space, specs, & manufacturing controls.
CommercialManufacture
Risk-based regulatory decisions (reviews and inspections); Manufacturing process improvements, within the approved design space, without further regulatory review.Reduction of post-approval submissionsReal-time quality control, leading to a reduction of end-product release testing
TechnologyTransfer
Demonstration of greater understanding of pharmaceutical and manufacturing sciences can create a basis for flexible regulatory approaches.
12
Industry is capitalising on Q8
NDA/CTD submissions are changing‘Here is my science, here is my manufacturing scheme which was developed through my science, here is how they link together’
– M Kovalycsik - Wyeth
FDA pilot programDesign Space submissions
Continuous process verification– Compliance policy 7132c.08
Already Q8 is delivering value to the Industry, the Regulators and, ultimately, the patient
13
Presentation Outline
Background to Q8 Experience of Q8 to date Implications of Q8 Future strategy for Q8
14
Understanding the full implications of Q8 is not easy
The Q8 EWG believes the core guideline needs exemplifying
What is Quality by Design?What’s the difference from the way pharmaceutical development has been approached and described until now?Can we help in distinguishing baseline or ‘minimum’ from enhanced?How exactly does the applicant describe the Design Space?
15
Q8 challenge example – What is Design Space?
Traditional Method:
Carry out the reaction at pH 2-5 and between 30 and 60C
= ‘Proven Acceptable Ranges’
5.0 pH2.0
60C
30C
How do we describe the <criterion>, relationship and associated control strategy?
Design Space:
Carry out the crystallisation to create particles at size/shape <criterion> varying the temperature, stirring rate and super saturation according to the relationship:
Size = f(temperature) + f(stirring) + f(super saturation)
16
Wider implications of Q8 development
Can we clearly articulate what we mean by Quality by Design and understand its implications for both the Industry and Regulators?
As we complete revision of Q8 should we add a glossary of key terms, perhaps illustrated through examples?
How should we address API development & manufacture for both chemical and biotech? Draft concept paper for NCE API available Biotech paper not endorsed by ICH
– Critical we assess implications of “Quality by Design”
Q8 is impacting the way we define specifications (Q6A & Q6B)
There may be other things needing consideration E.g. analytical methods
These issues likely to be raised at ICH quality strategy discussion
17
Presentation Outline
Background to Q8 Experience of Q8 to date Implications of Q8 Future strategy for Q8
18
Progression of Q8
EWG has changed its focus for the revision from parenterals to solid oral dosage forms
Because it provides the greatest opportunity (lots of background and expertise) and is most common dosage formWhen oral solids agreed, we will address the other types of dosage form
Illustrate QbD principles Examples drawn from EFPIA mock P2 documentEnsure that we are clear on Design Space
Step 2 date hard to predict
19
Progression should continue since Q8 is positively impacting Industry and Regulatory Practices
Science-based (Quality by Design) approaches will bring needed medicines to patients in more robust and effective way and unlock the innovative potential of the industryRegulators are responding supportively
FDA: • Development of elite teams comprising investigators, analysts and compliance
officers from field and CDER organisations : capable of making judgements about a firm’s risk management programmes, product and process knowledge, process capability and robustness of quality systems.
• Considering making revisions to its post-approval change reporting regulations (21 CFR 314.70) to accommodate more "regulatory flexibility" for drug makers operating within their pre-disclosed design space
– J Clark 28-8-06
EMEA: Revision of Variations Regulations• “We have come to the conclusion that the concepts laid down in these
guidelines – also taking into account the ongoing work of Q10 – could not be properly implemented in the EU without amendments to the Variations Regulations”
G Lalis, EC; 16-3-06
20
Ultimately, it’s all about structured KNOWLEDGE: this links with Q10
TPP Prod/Proc Design ControlDevelopment Space Strategy
Clin Dev
TechTransfer
CommProduction
Knowledge
21
Q8, Q9, Q10 – the opportunity
To deliver the ICH Vision and modernize Pharmaceutical Manufacturing and associated regulatory processes……….
Existing Existing GMPGMP’’ss
Quality by Design(Pharmaceutical
Development)
Quality Risk Management
The Regulatory Quality System
Our vision: The future Pharmaceutical Quality System
Quality Systems
Quality Systems (Q10)
For companies with :1. Good design and
control strategies2. Good Risk
Management strategies3. Good Quality Systems
Quality Risk Management
(Q9)
Quality by Design
(Q8)
Reduced regulatory burden:
• Reduction of submissions on changes/variations
• Inspection of quality systems
BOTH Industry and Regulators need to work together to change the current paradigm and mindsets……..
– Q8 / Q9 / Q10 providing a ‘once in a lifetime’ opportunity– Let us progress the concepts and guidelines with enthusiasm and optimism!
top related